Emalex Biosciences
Emalex Biosciences is a Chicago-based clinical-stage biopharmaceutical company created by Paragon Biosciences in 2018. The company develops novel treatments for central nervous system disorders, with its lead asset ecopipam — a first-in-class selective dopamine D1 receptor antagonist — in late-stage development for pediatric Tourette syndrome. In April 2026, Teva announced its acquisition of Emalex for $700 million.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountNov 2022
Mar 2021
Oct 2019
Jul 2018
Create a free account to see which investors have funded this company.
Create Free Account
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...
Global full-service clinical research organization (CRO) and scientific advisory partner for biot...
Global clinical research organization specializing in early-stage clinical trials and bioanalytic...
Healthcare company applying technology to drug development by building nimble biotech subsidiarie...
Neuralink is building a brain-computer interface for medical needs and greater human potential.
